Preclinical studies demonstrated that the successful suppression of MALAT1 and SAMMSON by antisense oligonucleotides (ASO) triggered cancer cell death in xenograft mouse models of multiple myeloma and melanoma, respectively [194,195], suggesting the potential use of ASOs for targeting lncRNAs as a therapeutic. This evidence concerns the gene SAMMSON and plasma cell myeloma.